---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000614"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:07:57.127703+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q1 2024 revenue $38M, net loss $26.8M; Kostaive on track for Q3 launch, cash runway through FY2027

## Summary
- Q1 2024 revenue $38.0M (down 53% YoY); net loss $26.8M ($1.00/share) vs net income $50.8M ($1.87) in Q1 2023.
- Cash $345.3M; runway extends at least three years to Q1 FY2027; expects future CSL milestones.
- Kostaive commercialization on track: initial 4M doses delivery in Q3; European MAA decision expected Q3.
- Phase 3 pivotal study for ARCT-2303 (XBB.1.5) initiated; ARCT-2138 flu Phase 1 topline data expected Q3.
- ARCT-810 (OTC) and ARCT-032 (CF) data updates on July 1, 2024; JP Morgan engaged to monetize ARCALIS JV stake.

## SEC filing metadata
- accession: 0001193805-24-000614
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000614/0001193805-24-000614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000614/e663590_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000614
- JSON: https://secwatch.observer/filing/0001193805-24-000614.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000614.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported the three months ended March 31, 2024 results: revenue $38.0 million.
  - Period: the three months ended March 31, 2024
  - Revenue: $38.0 million
  - Result: reported results
  source text: For the three months ended March 31, 2024, revenues were $38.0 million compared with $80.3 million for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000614/0001193805-24-000614-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.